NeuroMetrix, Inc. (Nasdaq: NURO,NUROW) announced today that its Quell ® Wearable Pain Relief Technology™ will be featured on the November 26 th episode of The Henry Ford Innovation Nation which airs on the CBS network on Saturday mornings as part of its "CBS Dream Team" lineup. Innovation Nation correspondent Alie Ward visited the NeuroMetrix offices in Waltham, MA in June to interview NeuroMetrix Founder & CEO, Shai Gozani, M.D., Ph.D. "We're proud of Quell and the impact it's having on chronic pain sufferers' lives. We appreciate the Innovation Nation team's interest in learning more about the Quell technology and sharing our story with its viewers," said Dr. Gozani. Check your local listings for The Henry Ford Innovation Nation this Saturday, November 26th on CBS. About QuellQuell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can start, stop, and adjust therapy discreetly via the optional Quell Relief app. Quell also offers advanced sleep tracking that provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive leg movements throughout the night. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information. About NeuroMetrixNeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck ®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.